Reuters logo
BRIEF-Janssen presents long term phase 3 efficacy and safety data of Sirukumab
June 14, 2017 / 4:40 PM / in 4 months

BRIEF-Janssen presents long term phase 3 efficacy and safety data of Sirukumab

June 14 (Reuters) - EMEA

* Janssen presents long term phase 3 efficacy and safety data of Sirukumab in rheumatoid arthritis patients who had an inadequate response and/or who were intolerant to anti-tnfs

* Janssen EMEA says “ long-term efficacy of sirukumab as shown in sirround-t study is encouraging”

* Janssen EMEA- investigators reported treatment with Sirukumab consistently increased levels of haemoglobin in adult patients with moderately to severely active RA

* Janssen EMEA says patients receiving sirukumab demonstrated clinically “meaningful” improvements from baseline through week 52 in quality of life measures Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below